AHA/ASA/ACCF EXPERT CONSENSUS DOCUMENT: SCIENCE ADVISORY
Percutaneous Device Closure of Patent Foramen Ovale for Secondary Stroke PreventionA Call for Completion of Randomized Clinical Trials A Science Advisory From the American Heart Association/American Stroke Association and the American College of Cardiology Foundation The American Academy of Neurology affirms the value of this science advisory
Patrick T. O'Gara, MD, FAHA, FACC, Chair,
Steven R. Messe, MD, FAHA,
E. Murat Tuzcu, MD, FAHA, FACC,
Gloria Catha, BA and
John C. Ring, MD, FACC
The optimal therapy for prevention of recurrent stroke or transient ischemic attack in patients with cryptogenic stroke and patent foramen ovale has not been defined. Although numerous observational studies have suggested a strong association between patent foramen ovale and cryptogenic stroke, a causal relationship has not been convincingly established for the majority of affected patients. Treatment choices include medical therapy with antiplatelet agents or vitamin K antagonists, percutaneous device closure, or open surgical repair. Whereas suture closure of an incidental patent foramen ovale is performed routinely during the course of an operation undertaken for another indication, primary surgical repair is rarely advocated in the current era. The choice between medical therapy and percutaneous device closure has been the subject of intense debate over the past several years, albeit one that has not been adequately informed by randomized, prospective clinical trial data to permit an objective comparison of the relative safety and efficacy of these respective approaches. Enrollment in clinical trials has lagged considerably despite frequent calls for participation from the US Food and Drug Administration and major professional societies. Completion and peer review of ongoing trials are critical steps to establish an evidence base from which clinicians can make informed decisions regarding the best therapy for individual patients. The present advisory strongly encourages all clinicians involved in the care of appropriate patients with cryptogenic stroke and patent foramen ovale—cardiologists, neurologists, internists, radiologists, and surgeons—to consider referral for enrollment in these landmark trials to expedite their completion and help resolve the uncertainty regarding optimal care for this condition.
Key Words: ACCF Expert Consensus Documents • stroke • patent foramen ovale • aneurysm • antiplatelet agents • anticoagulation • surgery
This article has been cited by other articles:
|
|
|
|
 
V. Delgado, F. van der Kley, M. J. Schalij, and J. J. Bax
Optimal imaging for planning and guiding interventions in structural heart disease: a multi-modality imaging approach
Eur. Heart J. Suppl.,
September 1, 2010;
12(suppl_E):
E10 - E23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Marsh and S. G. Keyrouz
Stroke Prevention and Treatment
J. Am. Coll. Cardiol.,
August 24, 2010;
56(9):
683 - 691.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Chandrashekhar
PFO and the Heart: More Than Meets the Eye!
J. Am. Coll. Cardiol. Img.,
August 1, 2010;
3(8):
840 - 842.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. I. Michelena, M. D. Abel, R. M. Suri, W. K. Freeman, R. L. Click, T. M. Sundt, H. V. Schaff, and M. Enriquez-Sarano
Intraoperative Echocardiography in Valvular Heart Disease: An Evidence-Based Appraisal
Mayo Clin. Proc.,
July 1, 2010;
85(7):
646 - 655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Meier
Catheter-Based Closure of the Patent Foramen Ovale
Circulation,
November 3, 2009;
120(18):
1837 - 1841.
[Full Text]
[PDF]
|
|
|
|
